Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX3 Genetically Stratified Trial for Antifungal Prophylaxis in AML
NCT03828773Recruiting
- Start
- Feb 2019
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Randomised, double-blind trial of posaconazole in invasive fungal infection (IFI) (4 arms). Primary endpoint: Cumulative incidence of proven and probable invasive mold infection (IMI) at 180 days. Started Feb 2019; status: recruiting.
02
Drugs
posaconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT03828773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03828773.